AstraZeneca Signs Deal to Tackle Japan's Drug Lag (Japan)
This article was originally published in PharmAsia News
Pharmaceutical giant AstraZeneca announced Sept. 26 it had entered a partnership with Tokyo's prestigious Keio University School of Medicine. Currently, there is a significant delay between the time drugs debut in Europe and North American and when they are made available to Japanese patients. By partnering with Keio, AstraZeneca hopes to solve this problem by increasing the number of early clinical trials conducted in Japan. (Click here for more
You may also be interested in...
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Drawing on the company’s Latin name, Viatris – the proposed combination of Mylan and Upjohn – has unveiled a logo and branding “capturing the company’s commitment to access, leadership and partnership.”
Having recently signed a gene therapy collaboration with Sarepta and received a positive opinion from the CHMP for its kidney transplant therapy, Sweden's Hansa has now raised a substantial sum in a "multiple times oversubscribed" placing.